Memory impairment and cholinergic dysfunction by centrally administered Aβ and carboxyl‐terminal fragment of Alzheimer's APP in mice
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by cognitive impairment and excessive deposition of neurite plaques (NPs). Although the pathogenic mechanism of AD is not exactly known, there is increasing evidence that amyloid beta protein (Aβ), which is the major constituent of NPs and is derived from amyloid precursor protein (APP), plays a key role in the neuronal degeneration in AD. However, because there are several discrepancies between Aβ deposition and neurodegeneration or cognitive impairment in AD, the possible effects of other cleavage products of APP need to be explored. We previously showed that a recombinant carboxyl‐terminal 105 amino acid fragment of APP (CT105) induced neurotoxicities both in vitro and in vivo. However, it is unclear whether learning and memory impairments and neurochemical changes are induced by CT 105. To elucidate the in vivo neurotoxicities of Aβ and CT105, we examined behavioral changes using a Y‐maze and a water maze task following a single intracerebroventricular injection of CT105 (68.5, 342 and 685 pmol) or Aβ 1–42 (685 pmol) to mice. We also quantified the changes in the acetylcholine (ACh) level and assayed mitochondrial pyruvate dehydrogenase (PDH) activity. CT105 caused much more significant impairments in cued, spatial, and working memory performances of mice in Y‐maze and water maze tasks in a dose‐dependent manner than Aβ 1–42 . Also, the mice injected with CT105 revealed significant decreases in ACh levels and reduced PDH activities in the cerebral cortex and hippocampus compared with the saline‐treated control and Aβ1–42‐treated groups. These results suggest that learning and memory impairment induced by centrally administered CT105 is in some way related to the reduced ACh levels and mitochondrial PDH activities and that CT105 is more potent than Aβ in inducing cognitive dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“However, a controversy surrounds the neurotoxicity of Aβ because Aβ peptides have exerted both neurotrophic and neurotoxic effects in cell culture (11).”
BackgroundYamada, K., Tanaka, T., Han, D., Senzaki, K., Kameyama, T., & Nabeshima, T. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00408.x · Cited by 238
Research works printed but not linked: 54
- 10.1002/ana.410140502 · DOI · Paper page
- Quirion R., 1993, Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release, J. Psychiatry Neurosci., 18, 226
- Palmer A. M., 1990, Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?, FASEB J., 4, 2745, 10.1096/fasebj.4.10.2165009 · DOI · Paper page
- 10.1046/j.1471-4159.1996.67051882.x · DOI · Paper page
- 10.1016/S0006-8993(00)02545-2 · DOI
- 10.1126/science.2111583 · DOI · Paper page
- 10.1046/j.1471-4159.1994.63020781.x · DOI · Paper page
- 10.1073/pnas.88.16.7247 · DOI · Paper page
- 10.1016/0197-4580(92)90053-Z · DOI · Paper page
- 10.1016/0006-8993(94)90193-7 · DOI
- 10.1523/JNEUROSCI.12-02-00376.1992 · DOI · Paper page
- 10.1073/pnas.90.16.7508 · DOI · Paper page
- 10.1016/0306-4522(93)90331-9 · DOI
- 10.1016/0197-4580(92)90059-7 · DOI
- 10.1016/0006-8993(95)00323-I · DOI
- 10.1023/A:1021691918517 · DOI · Paper page
- 10.1097/00005072-199301000-00004 · DOI · Paper page
- 10.1046/j.1471-4159.1996.66052034.x · DOI
- 10.1046/j.1471-4159.2000.741112.x · DOI
- 10.1097/00001756-199905140-00008 · DOI
- 10.1046/j.1471-4159.1996.67031172.x · DOI
- 10.1016/0006-291X(91)91572-T · DOI
- 10.1016/0014-5793(94)00851-5 · DOI
- 10.1126/science.2474201 · DOI · Paper page
- Seubert P., 1993, Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide, Vature, 361, 260
- Kim H. S., 2000, Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity, FASEB J., 14, 1508
- 10.1046/j.1471-4159.1998.71020875.x · DOI · Paper page
- 10.1073/pnas.89.22.10857 · DOI · Paper page
- 10.1073/pnas.89.8.3448 · DOI · Paper page
- Barelli H., 1997, Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases, Mol. Med., 3, 695, 10.1007/BF03401708 · DOI
- 10.1038/74656 · DOI · Paper page
- 10.1016/0024-3205(94)00853-1 · DOI
- 10.1016/0160-5402(86)90038-0 · DOI · Paper page
- 10.1007/BF00212843 · DOI · Paper page
- 10.1016/0197-4580(94)00155-3 · DOI · Paper page
- 10.1111/j.1471-4159.1982.tb04727.x · doi:10.1111/j.1471-4159.1982.tb04727.x
- Fulda S., 1988, Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid, J. Biol. Chem., 273, 33942, 10.1074/jbc.273.51.33942 · DOI · Paper page
- 10.1016/0896-6273(94)90165-1 · DOI · Paper page
- 10.1016/S0169-328X(99)00014-5 · DOI
- 10.1097/00001756-199710200-00006 · DOI · Paper page
- 10.1016/0006-8993(94)91697-7 · DOI
- 10.1046/j.1471-4159.1998.71020723.x · DOI · Paper page
- 10.1046/j.1471-4159.1995.64020749.x · DOI · Paper page
- Hoshi M., 1996, Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain, Proc.Natl. Acad. Sci. USA, 93, 2719, 10.1073/pnas.93.7.2719 · DOI · Paper page
- 10.1002/ana.410130116 · DOI · Paper page
- 10.1111/j.1471-4159.1980.tb12511.x · DOI
- 10.1016/0304-3940(80)90220-7 · DOI · Paper page
- 10.1111/j.1471-4159.1981.tb10817.x · doi:10.1111/j.1471-4159.1981.tb10817.x
- 10.1016/0304-3940(95)12058-C · DOI
- 10.1126/science.7058341 · DOI · Paper page
- 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I · DOI
- 10.1016/0006-291X(92)91730-E · DOI
- 10.1073/pnas.85.19.7341 · DOI · Paper page
- 10.1073/pnas.89.4.1345 · DOI · Paper page
Cited by
Turner, P. R., O’Connor, K., Tate, W. P., & Abraham, W. C. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00089-3 · Cited by 756
Suh, Y.-H., & Checler, F. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.469 · Cited by 467
Self-citationNixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400
Temporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1
Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., & Disterhoft, J. F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04551.x · Cited by 298
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice
Ohno, M., Cole, S. L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., Disterhoft, J. F., & Vassar, R. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.008 · Cited by 290
Metadata
- Authors
- Choi, S. H., Park, C. H., Koo, J. W., Seo, J.-H., Kim, H.-S., Jeong, S.-J., Lee, J.-H., Kim, S. S., & Suh, Y.-H.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2001-06-18
- Volume
- 15
- Issue
- 10
- Pages
- 1816-1818
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2122424729
- Cited by
- 47
- References
- 2
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Ministry of Science and Technology (HMP-98-N-6-0002)
- Ministry of Health and Welfare (HMP-98-N-6-0002)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Memory impairment and cholinergic dysfunction by centrally administered Aβ and carboxyl‐terminal fragment of Alzheimer's APP in mice. https://app.cochat.ai/papers/10.1096/fj.00-0859fje
- The paper
- Choi, S. H., Park, C. H., Koo, J. W., Seo, J.-H., Kim, H.-S., Jeong, S.-J., Lee, J.-H., Kim, S. S., & Suh, Y.-H. (2001). Memory impairment and cholinergic dysfunction by centrally administered Aβ and carboxyl‐terminal fragment of Alzheimer's APP in mice. The FASEB Journal. https://doi.org/10.1096/fj.00-0859fje
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.